IndustryCompany release

Revvity lifts 2026 guidance after 7% pro forma growth in third quarter

🇺🇸 Revvity, Inc. (RVTY) · Tue 03 Nov 2026

Revvity reported Q3 revenue of $729 million, with Life Sciences outpacing Diagnostics, and raised its full-year pro forma outlook while a China immunodiagnostics sale remains pending.

Revvity reported third-quarter revenue of $729 million for the period ended 4 October 2026, up from $699 million a year earlier. Pro forma revenue growth was 7%.

By segment, Life Sciences grew 11% and Diagnostics 4% on a pro forma basis. GAAP earnings per share from continuing operations were $0.56, while adjusted earnings per share came to $1.38.

The company raised its 2026 pro forma guidance to roughly $2.86 billion in revenue and adjusted earnings per share of $5.40 to $5.45.

The release also refers to the pending divestiture of Revvity's China immunodiagnostics business. Completion is expected by the end of 2027, subject to regulatory approvals. Revvity has scheduled an Investor Day for 13 November.

The summary available does not include further detail on drivers of growth, regional performance or the terms of the divestiture.

What it means for your team

  • Diagnostics teams and their partners should note the slower 4% pro forma growth in that segment relative to Life Sciences at 11%.
  • Market-access and supply-chain teams relying on Revvity's China immunodiagnostics products should monitor the divestiture, which still requires regulatory approvals and is not expected to close before the end of 2027.
  • The 13 November Investor Day may bring more detail on portfolio and strategy; no specifics are available yet.

Company's press release (SEC filing): Revvity, Inc. ↗

Article written by VigiEye from the official source (Revvity, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →